Enterosorption combined with granulocyte colony stimulating factor decreases melphalan gonadal toxicity.
Today due to improvements in cancer treatment there is an increasing number of long-term cancer survivors, many of whom suffer from infertility caused by malignancy itself and chemo- or radiotherapy. Also, anticancer therapy may cause myelosuppression. Presently granulocyte colony stimulating factor (G-CSF) is used for prevention and treatment of myelosuppression. Another treatment option used to decrease intoxication and ameliorate side effects of cancer therapy is sorption technology. The aim of our investigation was to study the efficiency of combined use of enterosorption and G-CSF to decrease gonadal toxicity of chemotherapy.


METHODS
Melphalan (L-PAM) injected i.v. at a single dose of 4 mg/kg to white inbred rats was used as gonadotoxic and myelosuppressing agent. Carbon enterosorbent C2 was administered by intragastric route as a suspension in saline at a dose of 5 ml per 1 kg of rats' body weight (or 900 mg/kg of the dry mass of enterosorbent) daily for 3 days before and for 7 days after L-PAM injection. G-CSF was injected once a day for 4 days starting from the next day after L-PAM administration at a dose of 50 µg/kg. Histological preparations of testicular tissues were examined by light microscopy.


RESULTS
Our findings have shown that melphalan caused marked damage of testicular tissues and seminiferous, especially spermatogenic epithelium. The most expressed protection of the histological structure of testes was observed when enterosorbent and G-CSF were used in combination.


CONCLUSIONS
Gonadal toxicity of chemotherapy could be efficiently decreased by the combined use of enterosorption and G-CSF.
I. Horbachevsky Ternopil State Medical University, Ternopil 46001, Ukraine.
O O
OO
Shevchuk
I. Horbachevsky Ternopil State Medical University, Ternopil 46001, Ukraine.
Ya Ya
YY
Bodnar
R.Y. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine, Kyiv 03022, Ukraine.
K I
KI
Bardakhivskaya
I. Horbachevsky Ternopil State Medical University, Ternopil 46001, Ukraine.
T V
TV
Datsko
I. Horbachevsky Ternopil State Medical University, Ternopil 46001, Ukraine.
A S
AS
Volska
I. Horbachevsky Ternopil State Medical University, Ternopil 46001, Ukraine.
К А
КА
Posokhova
R.Y. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine, Kyiv 03022, Ukraine.
V F
VF
Chekhun
R.Y. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine, Kyiv 03022, Ukraine.
V G
VG
Nikolaev
D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000633:toxicity*; D002244:Carbon / Q000627:therapeutic use; D016061:Enterosorption / Q000379:methods; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D008297:Male; D008558:Melphalan / Q000633:toxicity*; D019653:Myeloablative Agonists / Q000633:toxicity*; D009369:Neoplasms / Q000188:drug therapy; D020011:Protective Agents / Q000627:therapeutic use; D051381:Rats; D013737:Testis / Q000187:drug effects* / Q000473:pathology*
D018906:Antineoplastic Agents, Alkylating; D019653:Myeloablative Agonists; D020011:Protective Agents; D016179:Granulocyte Colony-Stimulating Factor; D002244:Carbon; D008558:Melphalan